Prof. Dr. Banu ÖZTÜRK

1. The effect of switching from ribociclib to palbociclib due to toxicity in hormone receptor-positive, HER2-negative metastatic breast cancer: a real-world, multicenter, retrospective study

Oruç A., Deliktaş Onur İ., Uyar G. C., ŞAHİN T. K., Tünbekici S., ARSLAN KAPUCİ A., et al.

Scientific Reports , cilt.16, sa.1, 2026 (SCI-Expanded, Scopus)

2. Real-world effectiveness and safety of brigatinib in advanced ALK-positive NSCLC: a nationwide multicenter study by the Turkish Oncology Group

Tunbekici S., Bal H., Kınıkoglu O., Arvas H., Muglu H., BİLİCİ A., et al.

Clinical and Translational Oncology , cilt.28, sa.8, ss.3160-3169, 2026 (SCI-Expanded, Scopus)

3. Evaluation of the predictive and prognostic performance of the PILE score in metastatic renal cell carcinoma

Güzel H. G., Aydın A. A., Hacıçavuşoğlu A., Balçık O. Y., Beypınar İ., ÖZTÜRK B., et al.

Frontiers in Medicine , cilt.13, 2026 (SCI-Expanded, Scopus)

4. Platelet-to-Albumin Ratio and Clinical Outcomes in IDH-Wildtype Grade 4 Diffuse Glioma

Guven O. D., Aydin A. A., Unlu A., Kaya H., Ovali F. S., Umit A., et al.

Journal of Clinical Medicine , cilt.15, sa.14, 2026 (SCI-Expanded, Scopus)

5. Real-World Outcomes of CDK4/6 Inhibitors in Germline BRCA1/2-Mutated Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: Turkish Oncology Group (TOG) Study

Seyyar M., Kalem A., Sali M., Karabuğa B., ŞAHİN T. K., Dişli A. K., et al.

Current Oncology , cilt.33, sa.6, 2026 (SCI-Expanded, Scopus)

6. Pretreatment Lactate Dehydrogenase-to-Albumin Ratio and Clinical Outcomes in Extensive-Stage Small Cell Lung Cancer: A Multicenter Real-World Study

Unlu A., Aydin A. A., Kars E. S., Ozturk O., Acun M., Baser M. N., et al.

Journal of Clinical Medicine , cilt.15, sa.9, 2026 (SCI-Expanded, Scopus)

7. Uric Acid-Driven Biomarkers and Clinical Outcomes in Metastatic Pancreatic Cancer: A Multicenter Real-World Cohort Study

Unlu A., Aydin A. A., Baser M. N., Turan M., KOÇER M., ÖZTÜRK B., et al.

Diagnostics , cilt.16, sa.9, 2026 (SCI-Expanded, Scopus)

8. Comparison of 6 cycles with 4 cycles of chemotherapy and atezolizumab in the first-line treatment of ES-SCLC: a retrospective multicenter analysis

Güzel H. G., KIVRAK SALİM D., Kılıçkap S., Kemal Y., Akosman C., Köseoğlu Ç., et al.

Oncologist , cilt.31, sa.4, 2026 (SCI-Expanded, Scopus)

9. Real-world effectiveness and safety of sacituzumab govitecan in patients with metastatic or unresectable locally advanced triple-negative breast cancer: A multicenter study by the Turkish Oncology Group

Tunbekici S., Sahin G., Ön S., Oruc A., Eryılmaz M. K., SAKİN A., et al.

International Journal of Cancer , cilt.158, sa.7, ss.1881-1890, 2026 (SCI-Expanded, Scopus)

10. Real-world comparison of cabozantinib and sunitinib in advanced non-clear cell renal cell carcinoma: A multicenter study by the Turkish Oncology Group

Şahin G., Tüzün E. K., Güzel H. G., Guliyev M., Dişli A. K., YAZICI M., et al.

International Journal of Cancer , cilt.158, sa.4, ss.1067-1079, 2026 (SCI-Expanded, Scopus)

11. Immune-related adverse events as predictors of pathological complete response in early-stage triple-negative breast cancer treated with pembrolizumab

Güren A. K., DEMİRCAN N. C., GÜMÜŞAY Ö., Şimşek E. T., Kemik F., KARAOĞLU Ç., et al.

Immunotherapy , cilt.18, sa.4, ss.317-326, 2026 (SCI-Expanded, Scopus)

12. Durvalumab-Based First-Line Chemoimmunotherapy in Advanced Biliary Tract Cancer: Real-World Outcomes and Prognostic Factors—A Turkish Oncology Group Study

Efil S. C., Kus F., Koylu B., Durukan B. M., Bayram S., Guzel H. G., et al.

Cancers , cilt.18, sa.1, 2026 (SCI-Expanded, Scopus)

13. Real-world outcomes of trastuzumab deruxtecan in patients with HER2+ metastatic breast cancer: Turkish oncology group multicenter study

ŞAHİN T. K., Kemik F., Muglu H., Acikgöz Yildiz B., Biter S., Tunbekici S., et al.

Therapeutic Advances in Medical Oncology , cilt.18, 2026 (SCI-Expanded, Scopus)

14. The HALLMOUNT Score: Development of a Novel Multidimensional Prognostic Model for Solid Tumors, with Initial Clinical Application in Grade 4 Adult-Type Diffuse Gliomas

Unlu A., Aydin A. A., ÖZTÜRK B., TÜRK C. Ç., YILDIZ M.

Medicina (Lithuania) , cilt.61, sa.12, 2025 (SCI-Expanded, Scopus)

15. Symptom Reporting Behaviors, Symptom Burden, and Quality of Life in Patients with Hormone Receptor–Positive Breast Cancer Undergoing Adjuvant Endocrine Therapy

Ulukal Karanci E., Güzel H. G., ÖZTÜRK B.

Current Oncology , cilt.32, sa.11, 2025 (SCI-Expanded, Scopus)

16. Pan-Immune-Inflammation Value as a Predictor of Long-Term Outcomes in Patients with Urothelial Carcinoma of the Bladder: A Pilot Study

Eren A. E., Aydin A. A., Aksaray E. E., Durak A., Unlu A., İSLAMOĞLU M. E., et al.

Current Oncology , cilt.32, sa.10, 2025 (SCI-Expanded, Scopus)

17. Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on efficacy: a Turkish Oncology Group (TOG) study

Yildirim H. C., Kapar C., Koksal B., Seyyar M., Sanci P. C., Guliyev M., et al.

Journal of Chemotherapy , cilt.37, sa.1, ss.69-75, 2025 (SCI-Expanded, Scopus)

18. Evaluating the Reciprocal Effects of COVID-19 Vaccines and Immunotherapy on Oncology Patients Receiving Immunotherapy

Onder A. H., Onder K. D., ÇEKİN Y., ÖZTÜRK B., KURTOĞLU E.

UHOD - Uluslararasi Hematoloji-Onkoloji Dergisi , cilt.35, sa.2, ss.131-149, 2025 (SCI-Expanded, Scopus, TRDizin)

19. The Gustave Roussy immune score as a novel biomarker for predicting survival in patients with isocitrate dehydrogenase wild-type glioblastoma treated with the Stupp protocol

Aydin A. A., Unlu A., Atabek N., Kayikcioglu E., YÜCEER K., Gorgulugil G. Z., et al.

Expert Review of Anticancer Therapy , cilt.25, sa.12, ss.1451-1458, 2025 (SCI-Expanded, Scopus)

20. Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma

Yildirim H. C., BAYRAM E., Chalabiyev E., Majidova N., Avci T., Güzel H. G., et al.

Journal of Chemotherapy , cilt.37, sa.6, ss.551-562, 2025 (SCI-Expanded, Scopus)

21. Health-related quality of life and psychosocial outcomes in long-term survivors treated with immune checkpoint inhibitors: a nationwide multicenter study

ŞAHİN T. K., Atalah F., Koylu B., Oruc A., Acarbay A., Karakok A., et al.

Frontiers in Immunology , cilt.16, 2025 (SCI-Expanded, Scopus)

22. Efficacy and safety of G-CSF prophylaxis in patients with extensive-stage small cell lung cancer receiving chemoimmunotherapy

Ilhan Y., Ucar G., Baser M. N., Guzel H. G., Efil S. C., Demir B., et al.

Expert Opinion on Pharmacotherapy , cilt.25, sa.11, ss.1555-1563, 2024 (SCI-Expanded, Scopus)

23. Leptin and leptin receptor expression in breast carcinomas and their relationship with clinicopathological features

Atalay Karacay I., SEZGİN ALİKANOĞLU A., SÜREN D., ÖZTÜRK B., KARAKAŞ B. R., Sezer C.

Human Pathology Reports , cilt.30, 2022 (Scopus)

24. Concordance of HER2 status tested by IHC and FISH in biopsy and surgical resection specimens and comparison with clinicopathological features in gastric carcinoma

Nergiz D., SEZGİN ALİKANOĞLU A., SÜREN D., Gömceli I., ÖZTÜRK B.

Indian Journal of Pathology and Microbiology , cilt.65, sa.2, ss.321-327, 2022 (SCI-Expanded, Scopus)

25. Microalbuminuria is associated with reduced cardiac cyclic variation of integrated backscatter signal in severe hypertension

Ceyhan C., AKAR H., Tekten T., Onbasili A. O., Karul A., Discigil B., et al.

Echocardiography , cilt.21, sa.6, ss.495-501, 2004 (Scopus)